Simulations Plus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
April 03, 2024 at 04:34 pm
Share
Simulations Plus, Inc. reported earnings results for the second quarter and six months ended February 29, 2024. For the second quarter, the company reported revenue was USD 18.31 million compared to USD 15.75 million a year ago. Net income was USD 4.03 million compared to USD 4.17 million a year ago. Basic earnings per share from continuing operations was USD 0.2 compared to USD 0.21 a year ago. Diluted earnings per share from continuing operations was USD 0.2 compared to USD 0.2 a year ago.
For the six months, revenue was USD 32.81 million compared to USD 27.71 million a year ago. Net income was USD 5.97 million compared to USD 5.42 million a year ago. Basic earnings per share from continuing operations was USD 0.3 compared to USD 0.27 a year ago. Diluted earnings per share from continuing operations was USD 0.29 compared to USD 0.26 a year ago.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.